m+Medelevator.RU
← Поиск публикаций
Thoracic cancer · 2023

Clinical definition of secondary resistance to immunotherapy in non-small cell lung cancer.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Huang Dingzhi, Lin Gen, Chu Qian, Hu Yi, Wang Jun, Wang Zhijie, Yang Fan, Zhong Wenzhao, Zhou Chengzhi, Zhu Bo, Ai Xinghao, Cao Baoshan, Cao Yabing, Chen Mingqiu, Chen Xiaohui, Chu Tianqing, Duan Jianchun, Fan Yun, Fang Yong, Feng Shuitu, Feng Weineng, Guo Hui, Han Chengbo, He Yong, Hong Shaodong, Hu Jie, Huang Meijuan, Huang Yan, Jiang Da, Jiang Kan, Jiang Richeng, Jin Bo, Jin Shi, Li Jisheng, Li Min, Li Ziming, Li Chao, Lin Jie, Liu Anwen, Liu Si-Yang Maggie, Liu Yutao, Liu Zhefeng, Liu Zhe, Liu Zhenhua, Liu Zhentian, Liu Zhigang, Lu Yuping, Lv Tangfeng, Ma Zhiyong, Miao Qian, Peng Min, Pu Xingxiang, Ren Xiu Bao, Shan Jianzhen, Shan Jinlu, Shen Peng, Shen Bo, Shi Meiqi, Song Yong, Song Zhengbo, Su ChunXia, Sun Jianguo, Tian Panwen, Wang Jinliang, Wang Feng, Wang Huijuan, Wang Jialei, Wang Qian, Wang Wenxian, Wang Yan, Wu Lin, Wu Fang, Xia Yang, Xie Congying, Xie Conghua, Xin Tao, Xiong Jianping, Xu Haipeng, Xu Song, Xu Yiquan, Xu Bin, Xu Chunwei, Yan Xiaolong, Yang Zhenzhou, Yao Wenxiu, Yu Yao, Feng Ye, Yu Zongyang, Yu Yongfeng, Yue Dongsheng, Zhang Haibo, Zhang HongMei, Zhang Li, Zhang Longfeng, Zhang Qiuyu, Zhang Tongmei, Zhang Bicheng, Zhao Jun, Zhao Mingfang, Zheng Xiaobin, Zhong Fengqiao, Zhou Jin, Zhou Penghui, Zhu Zhengfei, Zou Juntao, Zou Zihua

Аннотация

Immune checkpoint inhibitors (PD-1/PD-L1 and CTLA-4 blockade) have revolutionized the treatment landscape in non-small cell lung cancer (NSCLC). Secondary resistance to immunotherapy (IO), which poses a substantial challenge in clinical settings, occurs in several initial responders. Currently, new treatment approaches have been extensively evaluated in investigational studies for these patients to tackle this difficult problem; however, the lack of consistency in clinical definition, uniform criteria for enrollment in clinical trials, and interpretation of results remain significant hurdles to progress. Thus, our expert panel comprehensively synthesized data from current studies to propose a practical clinical definition of secondary resistance to immunotherapy in NSCLC in metastatic and neoadjuvant settings. In addition to patients who received IO alone (including IO-IO combinations), we also generated a definition for patients treated with chemotherapy plus IO. This consensus aimed to provide guidance for clinical trial design and facilitate future discussions with investigators. It should be noted that additional updates in this consensus are required when new data is available.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты